

FORM PTO-1449
MODIFIEDU.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
207596APPLICATION NO.
09/720,276INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Erickson et al.FILING DATE
December 21, 2000GROUP
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		APPLICATION OR PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ele	AA	5,766,842	06/16/1998	Heefner et al.			
	AB	5,753,660	05/19/1998	Sikorski et al.			
	AC	5,728,718	03/17/1998	Randad et al.			
	AD	5,723,490	03/03/1998	Tung			
	AE	5,705,500	01/06/1998	Getman et al.			
	AF	5,703,076	12/30/1997	Talley et al.			
	AG	5,502,060	3/26/1996	Thompson			
	AH	5,475,027	12/12/1995	Talley et al.			

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO**
ele	AI	WO 99/67417	12/29/1999	WIPO				
	AJ	WO 99/67254	12/29/1999	WIPO				
	AK	WO 99/65870	12/23/1999	WIPO				
	AL	WO 97/19055	05/29/1997	WIPO				
	AM	WO 96/28463	09/16/1996	WIPO				
	AN	WO 95/06030	03/02/1995	WIPO				
	AO	2,276,621	10/05/1994	UK				
	AP	WO 94/14793	07/07/1994	WIPO				
	AQ	WO 94/05639	03/17/1994	WIPO				
	AR	WO 94/04492	03/03/1994	WIPO				
	AS	WO 90/09191	08/23/1990	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ele	AT	Bone et al., <i>J. Am. Chem. Soc.</i> , 113, 9382 (1991)
	AU	Borman et al., <i>J. Gen. Virology</i> , 77(3), 419-426 (March 1996)
	AV	Erickson et al., <i>Science</i> , 249, 527-533 (1990)
	AW	Ghosh et al., <i>Bioorganic & Medicinal Chemistry Letters</i> , 8, 687-690 (March 1998)
	AX	Ghosh et al., <i>J. Medicinal Chemistry</i> , 36(16), 2300-2310 (August 1993)
	AY	Ghosh et al., <i>J. Medicinal Chemistry</i> , 36(2), 292-294 (January 1993)
	AZ	Ghosh et al., <i>J. Medicinal Chemistry</i> , 37(16), 2506-2508 (August 1994)
	BA	Ghosh et al., <i>J. Medicinal Chemistry</i> , 37, 1177-1188 (April 1994)
	BB	Gulnik et al., <i>Biochemistry</i> , 34(29), 9282-9287 (July 1995)
	BC	Ho et al., <i>J. Virology</i> , 68(3), 2016-2020 (March 1994)
	BD	Huff, <i>J. Med. Chem.</i> , 34(8), 2305-2314 (August 1991)
	BE	Kageyama et al., <i>Antimicrob Agents Chemother.</i> , 36, 926-933 (May 1992)
	BF	Kaplan et al., <i>PNAS USA</i> , 91, 5597-5601 (1994)

Emily L

7/08/04

FORM PTO-1449
MODIFIEDU.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
207596APPLICATION NO.
09/720,276INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Erickson et al.FILING DATE
December 21, 2000GROUP
Unassigned

BG	Kim et al., <i>J. Medicinal Chemistry</i> , 38(17), 1181-1182 (1995)
BH	Klabe et al., <i>Biochemistry</i> , 37(24), 8735-8742 (May 1998)
BI	Kramer et al., <i>Science</i> , 231, 1580-1584 (1996)
BJ	Lyle et al., <i>J. Med. Chem.</i> , 34(3), 1228-1230 (March 1991)
BK	Majer et al., <i>13th American Peptide Symposium</i> , Edmonton, Canada (1993)
BL	Martinez-Picado et al. <i>J. Virology</i> , 73(5), 3744-3752 (May 1999)
BM	McQuade et al., <i>Science</i> , 247, 454-456 (1990)
BN	Meek et al., <i>Nature</i> , 343(6253), 90-92 (January 1990)
BO	Meek, <i>J. Enzyme Inhibition</i> , 6(1), 65-98 (January 1992)
BP	Moore et al., <i>Perspect. Drug Dis. Design</i> , 1, 85-108 (1993)
BQ	Norbeck et al., <i>Ann. Reports Med. Chem.</i> , 26, 141-150 (1991)
BR	Otto et al., <i>PNAS USA</i> , 90, 7543-7547 (1993)
BS	Plattner et al., <i>Drug Discovery Technologies</i> , Clark et al., eds., Ellis Horwood, Chichester, England, 92-126 (1990)
BT	Rich et al., <i>J. Med. Chem.</i> , 33(5), 1285-1288 (May 1990)
BU	Roberts et al., <i>Science</i> , 248, 358-361 (1990)
BV	Tomasselli et al., <i>Int. J. Chem. Biotechnology</i> , 6, 6-27 (1991)
BW	Vacca et al., <i>J. Med. Chem.</i> , 34(3), 1225-1228 (March 1991)
BX	Vazquez et al., <i>J. Medicinal Chemistry</i> , 38(4), 581-584 (February 1995)

EXAMINER

C. Le

DATE CONSIDERED

7/08/04

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(b).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(b).

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/720,276
				Filing Date	March 7, 2001
				First Named Inventor	Erickson
				Group Art Unit	1648
Examiner Name	Le, E.				
Sheet	1	of	1	Attorney Docket Number	207596

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
<i>de</i> <div style="border-left: 1px solid black; height: 100px; margin-left: 10px;"></div>	BY	EP	0 337 714	A2	Merck & Co.	Oct. 18, 1989		
	BZ	EP	0 434 365	A2	Merck & Co.	June 26, 1991		
	CA	EP	0 528 661	A2	Merck & Co.	Feb. 24, 1993		
	CB	EP	0 539 192	B1	Merck & Co.	Apr. 28, 1993		
	CC	EP	0 534 511	A1	Merck & Co.	Mar. 31, 1993		
	CD	EP	0 550 924	A1	Merck & Co.	July 14, 1993		
	CE	WO	90/09191	A1	Schramm et al.	Aug. 23, 1990		+
	CF	WO	00/48466	A2	Okla. Med. Res. Found.	Aug. 24, 2000		

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
<i>de</i> <div style="border-left: 1px solid black; height: 150px; margin-left: 10px;"></div>	CG	Chakraborty et al., <i>Tetrahedron Letters</i> , 41, 10121-10125 (2000)		
	CH	Ghosh et al., <i>Drug Design and Discovery</i> , 10, 77-88 (1993)		
	CI	Ghosh et al., <i>J. Med. Chem.</i> , 36, 924-927 (1993)		
	CJ	Ghosh et al., 207 th American Chem. Soc. Nat'l Meeting, Medi 37 (March 13-17, 1994)		
	CK	Ghosh et al., 210 th American Chem. Soc. Nat'l Meeting, Medi 27 (Aug. 20-24, 1995)		
	CL	Ghosh et al., <i>Bioorganic & Med. Chem. Lett.</i> , 5 (1), 83-88 (1995)		
	CM	Ghosh et al., <i>Tetrahedron Letters</i> , 36 (4), 505-508 (1995)		
	CN	Ghosh et al., <i>J. Med. Chem.</i> , 39, 3278-3290 (1996)		
	CO	Ghosh et al., 216 th American Chem. Soc. Nat'l Meeting, Medi 229 (1998)		
	CP	Ghosh et al., <i>Bioorganic & Med. Chem. Lett.</i> , 8, 979-982 (1998)		
	CQ	Ghosh et al., <i>Tetrahedron Letters</i> , 39, 4651-4654 (1998)		
	CR	Ghosh et al., 39 th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., Session 89F, paper 928, (Sep. 26-29, 1999)		
	CS	Ghosh et al., <i>Antiviral Research</i> , 51, p. 26, Abstract 035 (2001)		
	CT	Ghosh et al., <i>Il Farmaco</i> , 56, 29-32 (2001)		
	CU	Ghosh et al., <i>J. Med. Chem.</i> , 44, 2865-2868 (2001)		
	CV	Holloway et al., <i>J. Med. Chem.</i> , 38, 305-317 (1995)		
	CW	Hong et al., <i>Science</i> , 290 (5489), 150-153, (Oct. 6, 2000)		
	CX	Huff et al., <i>Journal of Cellular Biochemistry</i> , p. 130, S 037 (Feb. 26-Apr. 17, 1994)		
	CY	Koh et al., <i>Antimicrob. Agents Chemother.</i> , 47, 3123-3129 (2003)		
	CZ	Ray et al., <i>Apoptosis</i> , 5, 509-514 (2000)		
<div style="border-left: 1px solid black; height: 40px; margin-left: 10px;"></div>	DA	Turner et al., <i>Biochemistry</i> , 40 (34), 10001-10006 (Aug. 28, 2001)		
	DB	Upadhyaya et al., <i>Arch. Virol.</i> , 140, 1945-1956 (1995)		
	DC	Walia et al., <i>Infection and Immunity</i> , 67, 5215-5222 (Oct. 1999)		
	DD	Yoshimura et al., <i>J. Virol.</i> , 1349-1358 (Feb. 2002)		

Examiner Signature <i>Emily Le</i>	Date Considered 7/08/04
------------------------------------	-------------------------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).